Luteinizing-hormone releasing hormone therapy and the risk of death from alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 1, 2010, Pages 85-89

  D'Amico, Anthony V ^a   Braccioforte, Michelle H ^b   Moran, Brian J ^b   Chen, Ming Hui ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Prostate Cancer Foundation of Chicago   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Alzheimer disease; Hormone therapy; Prostate cancer

Indexed keywords

CESIUM 131; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; RADIOISOTOPE;

ADJUVANT CHEMOTHERAPY; AGED; ALZHEIMER DISEASE; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRACHYTHERAPY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 77949483447     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31819cb8f4     Document Type: Article

References (25)

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004;351: 56-67.
2. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neuro. 1995;52:81-88.
3. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:631-641.
4. Neve RL, McPhie DL. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther. 2006;111:99-113.
5. Webber KM, Casadesus G, Atwood CS, et al. Gonadotropins: a cohesive gender-based etiology of Alzheimer disease. Mol Cell Endocrinol. 2007;2:260-262, 271-275.
6. Meethal SV, Smith MA, Boweb RL, et al. The gonadotropin connection in Alzheimer's disease. Endocrine. 2005;26:317-326.
7. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994;331:996-1004.
8. Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate cancer. Cancer. 2005;103:1615-1624.
9. Greene FL. Prostate. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6 ed. New York, NY: Springer; 2002:309-316.
10. Gleason DF and the Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology. Philadelphia, PA: Lea & Febiger; 1977:171-187.
11. Zec RF, Landreth ES, Vicari SK, et al. Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1992;6:89-102.
12. Agresti A. An Introduction to Categorical Data Analysis. 2nd ed. New York, NY: John Wiley & Sons; 2002:16-52.
13. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York, NY: John Wiley & Sons; 1999:106-140.
14. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of causespecific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88: 400-409.
15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16: 1141-1154.
16. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer; 2003:243-293.
17. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94: 496-509.
18. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 1998;280:969-974.
19. Webber KM, Perry G, Smith MA, et al. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res. 2007;5:177-183.
20. Bowen Rl, Verdile G, Liu T, et al. Luteinizing Hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004;279:20539-20545.
21. Casadesus G, Webber KM, Atwood CS, et al. Luteinizing Hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta. 2006; 1762:447-452.
22. Casadesus G, Milliken EL, Webber KM, et al. Increase in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol. 2007;269:107-111.
23. Bowen RL, Smith MA, Harris PL, et al. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res. 2002;70: 514-518.
24. Schneider LS, Olin JT. Clinical global impressions in alzheimer's clinical trials. Int Psychogeriatrs. 1996;8:277-290.
25. Nelson CJ, Lee JS, Gamboa MC, et al. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113:1097-1106.